Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2051 to 2100 of 2995 results for all

  1. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG329)

    Evidence-based recommendations on insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. This involves pulling back the parts of the prostate that are pressing on the urethra so that it's no longer blocked.

  2. Peripheral nerve-field stimulation for chronic low back pain (HTG309)

    Evidence-based recommendations on peripheral nerve-field stimulation for chronic low back pain. This involves implanting electrodes in the back, connected to a neurostimulator under the skin to mask the back pain by modulating the transmission of pain signals to the brain.

  3. Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

    Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.

  4. Patient Status Engine for wireless monitoring of vital signs (MIB271)

    NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .

  5. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

  6. AlignRT in breast cancer radiotherapy (MIB157)

    NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .

  7. LiMAx system for assessing the functional capacity of the liver (MIB168)

    NICE has developed a medtech innovation briefing (MIB) on LiMAx system for assessing the functional capacity of the liver .

  8. BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis (MIB32)

    NICE has developed a medtech innovation briefing (MIB) on BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis .

  9. OCS Heart system for heart transplant (MIB86)

    NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .

  10. The PolySoft hernia patch used with the ONSTEP technique to treat inguinal hernias (MIB9)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Polysoft hernia patch for use with the ONSTEP technique to treat inguinal hernias

  11. Prevena incision management system for closed surgical incisions (MIB173)

    NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .

  12. Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

    Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

  13. Patient decision aids

    (lung) conditions Asthma inhalers and climate change Show Full list of all PDAs choosing between medical or surgical abortion from 14...

  14. NICE Advice service

    NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,

  15. Consultancy service

    Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country

  16. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  17. Artificial intelligence in mammography (MIB242)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .

  18. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

    Evidence-based recommendations on rituximab for the first-line treatment of stage III–IV follicular lymphoma.

  19. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.

  20. Sleepio to treat insomnia and insomnia symptoms (HTG624)

    Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.

  21. Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)

    Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.

  22. Early value assessment interim statement (PMG39)

    This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need

  23. Faricimab for treating diabetic macular oedema (TA799)

    Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.

  24. Capecitabine for the treatment of advanced gastric cancer (TA191)

    Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.

  25. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

  26. Aflibercept for treating choroidal neovascularisation (TA486)

    Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.

  27. Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosis (TA127)

    Evidence-based recommendations on natalizumab (Tysabri) for treating rapidly evolving severe relapsing–remitting multiple sclerosis in adults.

  28. QuikRead go for C-reactive protein testing in primary care (MIB78)

    NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care

  29. Deep brain stimulation for Parkinson's disease (HTG7)

    Evidence-based recommendations on deep brain stimulation for Parkinson's disease. This involves planting electrodes into the brain and generating electrical currents to reduce the problems caused by Parkinson's disease.

  30. Intralesional photocoagulation of subcutaneous congenital vascular disorders (HTG56)

    Evidence-based recommendations on intralesional photocoagulation of subcutaneous congenital vascular disorders. This involves inserting a laser fibre into the lesion to deliver the light deep within it.

  31. Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG482)

    Evidence-based recommendations on transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves using heated water vapour to destroy some of the prostate tissue.

  32. High-intensity focused ultrasound for symptomatic benign thyroid nodules (HTG504)

    Evidence-based recommendations on high-intensity focused ultrasound for symptomatic benign thyroid nodules in adults. This involves using heat made by high-frequency sound waves to destroy the nodule.

  33. Endovascular atrial septostomy (HTG53)

    Evidence-based recommendations on endovascular atrial septostomy. This involves inflating a balloon passed into the heart with a catheter to try to make the hole bigger so that it does not close up completely.

  34. Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction (HTG297)

    Evidence-based recommendations on percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction. This involves implanting a replacement valve with a wire mesh tube called a stent.

  35. Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children (HTG149)

    Evidence-based recommendations on the serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children. This involves cutting and stapling the bowel in a zig-zag pattern to narrow and lengthen it.

  36. Radiotherapy for age-related macular degeneration (HTG24)

    Evidence-based recommendations on radiotherapy for age-related macular degeneration. This involves using radiation to destroy the new blood vessels, with the aim of slowing down sight loss.

  37. Transperineal template biopsy and mapping of the prostate (HTG237)

    Evidence-based recommendations on transperineal template biopsy of the prostate. This involves inserting many fine needles though the skin between the scrotum and the anus in order to obtain tissue samples from the prostate for testing.

  38. Endoscopic injection of bulking agents for gastro-oesophageal reflux disease (HTG28)

    Evidence-based recommendations on endoscopic injection of bulking agents for gastro-oesophageal reflux disease. This involves injecting a filler into the junction using a catheter to make the entry to the stomach narrower, so that the contents of the stomach cannot pass back.

  39. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

  40. PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)

    NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .

  41. Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

    Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

  42. Cabotegravir for preventing HIV-1 in adults and young people (TA1106)

    Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.

  43. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

  44. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

  45. Archimedes for biopsy of suspected lung cancer (MIB211)

    NICE has developed a medtech innovation briefing (MIB) on Archimedes for biopsy of suspected lung cancer .

  46. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over (TA1147)

    Evidence-based recommendations on vorasidenib (Voranigo) for treating grade 2 astrocytoma or oligodendroglioma in people 12 years and over.

  47. International collaboration

    International collaboration with NICE

  48. Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma (HTG470)

    Evidence-based recommendations on microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma in adults. This involves putting a tiny gelatin tube (stent) under the skin at the base of the eye to create a new drainage channel for excess fluid.

  49. Extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome (HTG248)

    Evidence-based recommendations on extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome. This involves using a machine to deliver sound waves to the painful area to stimulate healing.

  50. Optical coherence tomography to guide percutaneous coronary intervention (HTG332)

    Evidence-based recommendations on optical coherence tomography to guide percutaneous coronary intervention. This involves using near-infrared light to produce high-resolution images of blood vessel walls.